Thursday, 19 September
From Clinical Trials to Rwd With Faricimab: What You See is What You Get
19 September, 13:30 – 14:30 CEST
113/114
Chairperson(s):
A. Khanani, USA
A Turning Point in nAMD
19 September, 13:30 – 14:30 CEST
112
Chairperson(s):
R. Gale, UK
Patient-centric individualisation of treatment: Will AI introduce a paradigm shift in the treatment of retinal diseases?
19 September, 13:30 – 14:30 CEST
212
Chairperson(s):
B. Kuppermann, USA
Friday, 20 September
EURETINA IME Platform on Dry AMD & GA: Implementing Modern Diagnosis and Management Approaches in Today’s Practice
20 September, 09:45 - 10:45 CEST
116/117
Chairperson(s):
A. Loewenstein, ISRAEL
Alcon Eye to Eye: Innovation, Precision & Integration
20 September, 09:45 - 10:45 CEST
113/114
Chairperson(s):
G. Pertile, ITALY
The Real World Impact of Faricimab on Clinic Capacity
20 September, 09:45 - 10:45 CEST
115
Chairperson(s):
D. Wong, CANADA
Optogenetic Therapies For Retinal Degenerative Disease – Clinical Developments And Updates
20 September, 09:45 - 10:45 CEST
118/119
Chairperson(s):
J. Monés, SPAIN,
F. Bandello, ITALY (Co-Chair)
Recent Advancements in Diagnosis & Management of X-linked Retinitis Pigmentosa
20 September, 09:45 - 10:45
212
Chairperson(s):
B. Leroy, BELGIUM
Precision medicine: The future of DME and RVO
20 September, 13:45 - 14:45 CEST
113/114
Chairperson(s):
L. Kodjikian, FRANCE
Advancing Retina Disease Management – Part 1: the Crucial Role of Diagnostic Imaging Today and Tomorrow
20 September, 13:45 - 14:45 CEST
111
Chairperson(s):
M. Munk, SWITZERLAND
A Turning Point in DME
20 September, 13:45 - 14:45 CEST
112
Chairperson(s):
M. Stewart, USA
Changing the nAMD Game Plan with Faricimab: Dual Pathway, Drying and Durability.
20 September, 13:45 - 14:45 CEST
211
Chairperson(s):
F. Holz, GERMANY
Imaging Innovations - Advancing Research and Patient Care
20 September, 13:45 - 14:45 CEST
212
Chairperson(s):
C. Mody, GERMANY
All Eyes on Geographic Atrophy
20 September, 17:45 - 18:45 CEST
112
Chairperson(s):
S. Bakalash, USA
Controversies on modern laser treatments for retina and vitreous
20 September, 17:45 - 18:45 CEST
115
Chairperson(s):
A. Filloy, SPAIN
Changing the DME Game Plan With Faricimab: Dual Pathway, Drying and Durability
20 September, 17:45 - 18:45 CEST
111
Chairperson(s):
P. Scholttmann, ARGENTINA
The Treatment of Neovascular AMD. Introducing Bevacizumab Gamma – the First Approved Ophthalmic Formulation of Bevacizumab
20 September, 17:45 - 18:45 CEST
212
Chairperson(s):
F. Bandello, ITALY
Saturday, 21 September
EURETINA IME Platform on Digital Visualization: New Technologies Bring Key Improvements to the Real World
21 September, 10:15 - 11:15 CEST
116/117
Chairperson(s):
G. Pertile, ITALY
Elevating Patient Outcomes With Single Capture Ultra-Widefield Imaging
21 September, 10:15 - 11:15 CEST
115
Chairperson(s):
S. Sadda, USA
Two Year Benefits in Clinical and Anatomical Measures in Intermediate Dry AMD Patients Treated With the Valeda Light Delivery System
21 September, 10:15 - 11:15 CEST
111
Chairperson(s):
M. Munk, SWITZERLAND
Clinical Insights on Retinal Morphology and Function With Deep Learning and Algorithms
21 September, 10:15 - 11:15 CEST
212
Chairperson(s):
T. Sakamoto, JAPAN
GA Patient Management for Tomorrow
21 September, 13:00 - 14:00 CEST
116/117
Chairperson(s):
A. Loewenstein, ISRAEL,
F. Holz, GERMANY
Protection of Vision and Structure in GA
21 September, 13:00 - 14:00 CEST
113/114
Chairperson(s):
U. Chakravarthy, IRELAND
Is Continuous Drug Delivery the Key to Transforming Long-term Outcomes in Retinal Diseases?
21 September, 13:00 - 14:00 CEST
115
Chairperson(s):
M. Figueroa, SPAIN
Advancing Retina Disease Management – Part 2: Managing Complicated Cases in Vitreoretinal Surgery
21 September, 13:00 - 14:00 CEST
111
Chairperson(s):
P. Stalmans, BELGIUM
Up for debate: points of view in retinal care
21 September, 13:00 - 14:00 CEST
112
Chairperson(s):
J. Kitchens, USA, P. Patel, UK
Improving on the Standard of Care in nAMD: Addressing the VEGF-C and -D Pathways
21 September, 13:00 - 14:00 CEST
211
Chairperson(s):
A. Khanani, USA
A Fully Immersive Visualization Experience
21 September, 13:00 - 14:00 CEST
212
Chairperson(s):
C. Mateo, SPAIN
